Endocrine-Related Cancer

Endocrine-Related Cancer logo. New Research: GLP1 receptor agonism alters growth and therapeutic response in prostate cancer. By Soumen Bera et al. Published by Bioscientifica logo. Society for Endocrinology logo.

New research by Soumen Bera et al. supports a model where GLP1R agonism blocks oncogenic pathways and growth of prostate cancer cells, pointing to potential therapeutic applications of semaglutide in advanced prostate cancer.

👉 Read the article: doi.org/10.1530/ERC-25-0185

Collection Curated by Prof. Karel Pacak. Incoming Editor-in-Chief of Endocrine-Related Cancer. Images of PDFs of a selection of the selected articles. Endocrine-Related Cancer logo.

⭐ Which articles are shaping the conversation in endocrine oncology?

Our incoming Editor‑in‑Chief, Professor Karel Pacak, has curated his first Editors’ Choice Collection.

📚 Explore the collection: erc.bioscientifica.com/page/edchoice/editors-choice

Endocrine-Related Cancer logo. New Review: Towards harmonised paediatric thyroid cancer care: adult comparisons and gaps. By Michaela Kuhlen, Marina Kunstreich, and Antje Redlich. Published by bioscientifica logo. Society for Endocrinology logo.

A new narrative review by Michaela Kuhlen, Marina Kunstreich and Antje Redlich explores how paediatric and adult DTC differ across biology, presentation, treatment strategies and guidelines, highlighting the need for harmonised, age‑specific approaches.

doi.org/10.1530/ERC-25-0191

Top left: Endocrine-Related Cancer logo. Text: Explore and contribute to expert-curated research on hormone-related cancers. Bottom right: Society for Endocrinology logo.

Spotlighting our latest completed collections & our open collections for submissions.

✅ 𝗖𝗼𝗺𝗽𝗹𝗲𝘁𝗲𝗱 𝗖𝗼𝗹𝗹𝗲𝗰𝘁𝗶𝗼𝗻𝘀:
🔎 𝙍𝙀𝙏@𝙏𝙝𝙞𝙧𝙩𝙮 - bit.ly/4p9qspY
🔬 𝙏𝙝𝙚 𝙒𝙖𝙧𝙗𝙪𝙧𝙜 𝙀𝙛𝙛𝙚𝙘𝙩 - bit.ly/4rb6eOs

💡 𝗢𝗽𝗲𝗻 𝗳𝗼𝗿 𝗦𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀:
🌱 𝙃𝙚𝙧𝙞𝙩𝙖𝙗𝙡𝙚 𝙀𝙣𝙙𝙤𝙘𝙧𝙞𝙣𝙚 𝘾𝙖𝙣𝙘𝙚𝙧𝙨 - bit.ly/43A22O7
🧠 𝙋𝙞𝙩𝙪𝙞𝙩𝙖𝙧𝙮 𝙏𝙪𝙢𝙤𝙪𝙧𝙨 - bit.ly/4p9qTk6

Headline text: Welcome our new Associate Editor... Headshot of Joakim Crona, MD, PhD Text reads: Joakim Crona, MD, PhD, Associate Professor, Uppsala University, Sweden Bottom left: Endocrine-Related Cancer logo. Bottom right: Society for Endocrinology logo.

Please join us in welcoming Dr. Crona to the Endocrine-Related Cancer community.

Dr. Crona is Associate Professor at Uppsala University, Sweden, and a clinical oncologist with a special interest in endocrine neoplasia.🚀

Endocrine-Related Cancer. 2025 Best Paper Award. Bioscientifica. Society for Endocrinology.

🏆 As we approach the end of 2025, we’re launching the Endocrine-Related Cancer Best Paper Award - celebrating the most outstanding articles published in 2025.

Papers will be selected by our editorial leadership, with 1st place awarded £1000 💜 Stay tuned, selection will take place in 2026!

Today, we stand with the global community in recognising everyone affected by neuroendocrine cancer.

At Endocrine-Related Cancer, we remain committed to publishing high-quality research that advances understanding of NETs to optimise patient care.

🔗 lnkd.in/eBY6uA_r

#WorldNeuroendocrineCancerDay

Special Collection. Advances and Innovation: The Next Chapter in Pheochromocytoma and Paraganglioma. Endocrine-Related Cancer.

We’re excited to announce a new Special Collection featuring the most significant clinical & scientific presentations from the 7th International Symposium on Pheochromocytoma.

🔗 For more info: lnkd.in/d3gyVVbg

Collection Editors: Prof. Isabelle Bourdeau, Prof. Karel Pacak
& Prof. André Lacroix

🎉 Excited to share our new publication!

Targeted inhibition of netrin–DCC axis with NP137 reverses netrin-driven survival in vitro & reduces high-grade pancreatic NEN progression in vivo.

Potential therapeutic strategy for aggressive PNENs?

bit.ly/435pKBx

@endocancer.bsky.social

New Research: First-line lenvatinib and sorafenib in RR-DTC from a shared real-life context in Endocrine-Related Cancer. By Vincenzo Marotta et al. Published by Bioscientifica. Society for Endocrinology.

Lenvatinib is preferred over sorafenib as first-line therapy for RR‑DTC due to superior PFS.

Vincenzo Marotta et al. compared both MKIs in a real‑world, treatment‑naïve cohort: lenvatinib showed higher activity, but no OS benefit.

Subscribers can read the article: doi.org/10.1530/ERC-24-0215

New Research: Neoadjuvant palbociclib in women with operable, hormone receptor-positive breast cancer in Endocrine-Related Cancer. By Takayuki Ueno et al. Figure 1. Study flow diagram. Citation: Endocrine-Related Cancer 32, 9; 10.1530/ERC-24-0353

🧬 Results from clinical trial NCT03969121: Neoadjuvant Hormonal Therapy Plus Palbociclib in Operable, Hormone Sensitive and HER2-Negative Primary Breast Cancer.

Now available in Endocrine-Related Cancer #OpenAccess: doi.org/10.1530/ERC-24-0353

Endocrine-Related Cancer. Exciting opportunity to join our Editorial Board. "The programme allowed me to dip my toes into the editorial side of peer review, to which I had not previously been exposed." Amy Dwyer, PhD. Current Endocrine-Related Cancer Early-Career Editor. Society for Endocrinology.

Early-Career Editor Opening!

A great opportunity for early-career researchers to build editorial experience, gain mentorship & shape research.

To apply, send your CV and cover letter to erc@bioscientifica.com by 7 Nov 2025.

Questions? Reach out to erc@bioscientifica.com

NEW RESEARCH: Anlotinib in progressive RAI-refractory differentiated thyroid cancer: long-term results and PET/CT prognostic markers in Endocrine-Related Cancer. By Di Sun et al. Published by Bioscientifica. Society for Endocrinology.

New research by Di Sun et al. investigates the long-term efficacy of anlotinib in patients with progressive RAIR-DTC and explores the predictive potential of PET/CT parameters.

🔗 Subscribers of Endocrine-Related Cancer can read the full article: doi.org/10.1530/ERC-25-0027

Locoregional progression and surgical indications in stage IV asymptomatic SI-NETs in Endocrine-Related Cancer. By Branislav Klimácek et al. Figure 2. Kaplan−Meier estimates of time to symptom onset in initially asymptomatic patients. A full color version of this figure is available at https://doi.org/10.1530/ERC-25-0205. Citation: Endocrine-Related Cancer 32, 8; 10.1530/ERC-25-0205 Published by Bioscientifica. Society for Endocrinology.

New retrospective cohort study by Branislav Klimacek et al. explores the non-operative management of initially asymptomatic patients diagnosed with small intestine neuroendocrine tumors, raising questions about current guidelines.

Read the full study here #OpenAccess: doi.org/10.1530/ERC-25-0205

Register Now! 2025 Margie & Robert E. Petersen. Neuroendocrine Tumor Research Symposium. Breakthroughs today, cures tomorrow. Location: Boston, Massachusetts. Date: November 17-19.

Be part of the global #neuroendocrinecancer research conversation in Boston, November 17-19.

The NETRF (@netrf.org) Annual Research Symposium brings together expert researchers to share leading-edge science and learn from each other.

Register now: bit.ly/4nQ9goU

#NETresearch #cancerresearch

Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer | OncLive Neoadjuvant palbociclib plus endocrine therapy did not improved PEPI scores in operable hormone receptor–positive breast cancer.

Neoadjuvant Palbociclib Plus Endocrine Therapy Does Not Improve PEPI Scores in Resectable HR+ Breast Cancer
#BreastCancer #BCSM @endocancer.bsky.social
www.onclive.com/view/neoadju...

Explore the latest in #pheochromocytoma & #paraganglioma research with Endocrine-Related Cancer’s (@endocancer.bsky.social) special collection, featuring recent advances in genetics, metabolomics, nuclear medicine & more.
Explore the collection: erc.bioscientifica.com/page/PPGL

New Research: Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer in Endocrine-Related Cancer. By Vikki L Poole et al. Published by Bioscientifica. Society for Endocrinology. Figure 1. Phosphorylated PBF represses RAIU in breast cancer cells. (A) Left – schematic of the interaction between NIS and PBF proteins tagged at the C-terminus with the NanoLuc luciferase subunits LgBiT and SmBiT, respectively. In close proximity, LgBiT and SmBiT form a functional enzyme that uses the substrate furimazine to produce a high-intensity, luminescent signal. Created using Alphafold (59, 60) and BioRender. Right – NanoBiT analysis of NIS:PBF interaction in MCF-7 cells, with bar graph showing results at 20 min post-addition of Nano-Glo live cell assay substrate. (B) Co-immunoprecipitation assay showing PBF-HA and NIS-MYC interaction in MCF-7 breast cancer cells. (C) Schematic of PBF highlighting the overlapping phosphorylation site and endocytosis motif at the C-terminus, and the PBF-Y174A and E170_N172delinsAAA (PBF-EEN MUT) mutants. (D) Western blot showing the phosphorylation status of PBF-Y174A and PBF-EEN MUT compared with PBF-WT in MCF-7 cells. (E) Immunofluorescent images showing PBF-WT, PBF-Y174A and PBF-EEN MUT localisation in MCF-7 cells. (F) Immunofluorescent images showing subcellular localisation following the co-transfection of NIS-MYC (green) with VO, PBF-WT, PBF-Y174A or PBF-EEN MUT (red) in MCF-7 cells. Co-localisation is seen in yellow. (G) The effect of PBF and phosphomutants (Y174A/EEN-MUT) on RAIU in MCF-7 (i) and MDA-MB-231 (ii) cells transiently co-transfected with NIS-MYC. (H) The effect of PBF and phosphomutants (Y174A/EEN-MUT) on RAIU in MCF-7 cells treated with ATRA and dexamethasone. VO = vector only control. Bars = 10 μm. n = 3 for all experiments. Error bars = SEM. Significance shown compared with VO unless otherwise shown...Endocrine-Related Cancer 32, 8; 10.1530/ERC-24-0312

🔬 Discovery of a novel sodium iodide symporter regulatory pathway in breast cancer cells.

Vikki L Poole et al. opens new therapeutic avenues in #BreastCancer by mapping sodium iodide symporter regulation & pinpointing targets to boost radioiodide avidity.

Read #OpenAccess: doi.org/10.1530/ERC-...

New Research: Heme-oxygenase-1: a key player in thyroid carcinoma development in Endocrine-Related Cancer. By Exequiel Gonzalo Alonso et al. Graphical Abstract. Published by Bioscientifica. Society for Endocrinology.

New research by Exequiel Gonzalo Alonso et al. uncovers a protumor role for HO-1 in thyroid cancer by enhancing proliferation, migration & cell cycle progression. 🔎

🎯Could HO-1 be a therapeutic target?

Subscribers can read the research: doi.org/10.1530/ERC-25-0177

#ThyroidCancer #CancerResearch

Special Collection: Pituitary Tumours: Scientific Discoveries, Clinical Advances and Contested Paradigms. Endocrine-Related Cancer. Collection Editors: Dr. Sunita M. C. De Sousa, MD, PhD Dr. Frederic Castinetti, MD, PhD Dr. Henriett Butz, MD, PhD Dr. Adrian F. Daly, MD, PhD

🧠Contribute to Endocrine-Related Cancer's new Special Collection on pituitary tumours!

We welcome basic, translational & clinical studies that advance understanding & showcase innovations in the field.

📩Submit your proposal to: erc@bioscientifica.com
🌐More info: bit.ly/4mUXslc

Targeting RET in medullary thyroid cancer in Endocrine-Related Cancer. By Kate Newbold and Leslie Cheng. This paper forms part of the themed collection RET@Thirty: Three Decades of Remarkable Progress. The Guest Editors for this collection were Tom Kurzawinski, Neil McDonald and Kate Newbold.

🎯Targeting RET in medullary thyroid cancer has played a key role in therapeutic strategies in the past decade.

A new review by Kate Newbold and Leslie Cheng explores targeted and selective RET therapies, and highlights the challenge of resistance.

🔗 doi.org/10.1530/ERC-24-0291

Follow us on LinkedIn. LinkedIn logo. Endocrine-Related Cancer logo.

🌱Endocrine-Related Cancer is officially on LinkedIn!

Follow our new profile to stay up to date with the latest articles, special collections and updates from the journal.

🌐 linkedin.com/company/endocrine-related-cancer/

#MedSky #CancerResearch #EndocrineOncology #HormoneCancers

Endocrine-Related Cancer. Themed Collection: Systems Biology Approaches in Hormone Dependent Cancer Research. New Review: Systems biology successes and areas for opportunity in prostate cancer in Endocrine-Related Cancer. By Michael V Orman et al.

✨ Systems biology approaches are reshaping our understanding of cancer.

Latest review by Michael V Orman et al. (@cupharmacology.bsky.social‬) highlights the successes & potential of these approaches in bettering our understanding of prostate cancer.

👉 #OpenAccess - doi.org/10.1530/ERC-25-0067

Endocrine-Related Cancer. New Associate Editor. Professor Alfred Lam. Professor of Pathology, Griffith University, Australia. Latest Research: Rising incidence of follicular thyroid carcinoma and oncocytic carcinoma of the thyroid. By Steven Weller, Cordia Chu, and Alfred King-yin Lam

🌟We are delighted to announce that Prof. Alfred Lam, Professor of Pathology at Griffith University, has joined Endocrine-Related Cancer's editorial board as an Associate Editor.

👉 Explore his recent research article on the rising incidence of thyroid cancer: doi.org/10.1530/ERC-24-0326

The Nuclear Medicine Pilot Research Grant in Neuroendocrine Tumors (NETs). Submissions Now Open. Proposal Due August 31, 2025. ERF Logo. NETRF logo.

Sponsored by @netrf.org, this $100,000 grant is designed to help an early-career, basic or clinical scientist conduct novel and innovative #NETs research.

Learn more: mierf.org/to-apply/

#neuroendocrinecancer #earlycareerresearcher

New Research: DNA-PKcs inhibition as a therapeutic approach for differentiated thyroid cancer in Endocrine-Related Cancer. By Shu-Fu Lin et al. Society for Endocrinology. Published by bioscientifica.

🎯Could DNA-PKcs be a potential target for differentiated thyroid cancer therapy?

Recent preclinical research by Shu-Fu Lin et al. reveals that M3814, a DNA-PKcs inhibitor, has significant potential in treating DTC.

🔗Explore the results: doi.org/10.1530/ERC-25-0031

New Review in Emerging Leaders 2025 Special Collection. Impact of treatment on quality of life in neuroendocrine neoplasm survivors in Endocrine-Related Cancer. By Roberta Modica et al. Endocrine-Related Cancer.

How do treatments for neuroendocrine neoplasms impact quality of life?

A new review explores the impact of existing therapies such as somatostatin analogs, radioligand therapy, multikinase inhibitors & chemotherapy on quality of life in #NEN survivors.

📖 Read more: doi.org/10.1530/ERC-24-0303

Endocrine-Related Cancer. Incoming Editor-in-Chief, Dr Karel Pacak. "It is a great honor to assume the role of Editor-in-Chief of Endocrine-Related Cancer, a journal fully committed to raising awareness of endocrine cancers among healthcare providers by supporting excellence in basic and clinical research, high-quality studies, and evidence-based guidelines." Published by Bioscientifica. Society for Endocrinology.

✨We are thrilled to welcome Dr. Karel Pacak as the incoming Editor-in-Chief of Endocrine-Related Cancer!

Dr. Pacak's term begins on 1st January 2026.

We are excited for this next chapter, driven by his expertise and vision 🚀

The special collection in @endocancer.bsky.social - "From Discovery Science to the Clinic - Heritable Endocrine Cancers and Related Disorders" is open & calling for contributions. Edited by myself, Lois Mulligan & Joanne Ngeow in memory of Prof Charis Eng erc.bioscientifica.com/page/heritab... 🧪

Endocrine-Related Cancer. New Open-Access Research: Plasma metabolomics for the preoperative diagnosis of parathyroid carcinoma. By Jinheng Xiao et al. Published by Bioscientifica. Society for Endocrinology.

🧪New research by Jinheng Xiao et al. explores the distinct metabolic profiles of parathyroid carcinoma and parathyroid adenoma, identifying promising biomarkers for preoperative diagnosis of parathyroid carcinoma.

Read the full article #OpenAccess: doi.org/10.1530/ERC-24-0192